Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunoviaâ€™s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
10/06/26	0.1824 kr	-2.04%	750

Delayed Quote London S.E.

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - London S.E. Other stock markets 19:45:34 03/11/2025 +04			5-day change	1st Jan Change
31.92 ^SEK	-32.03%		+14,213.90%	+13,658.62%

06-10	Immunovia: Published study bolsters evidence for PancreaSure	FW
06-10	Immunovia Publishes Final Affirm Study Results in Journal of Clinical Oncology Confirming Strong Diagnostic Performance of Pancreasure	CI

Market Cap	121M 12.86M 11.1M 10.23M 9.58M 17.95M 1.22B 18.23M 47.1M 595M 48.25M 47.22M 2.06B	P/E Ratio 2026 *	-1.8x	P/E Ratio 2027 *	-4.49x
Enterprise Value	53.81M 5.73M 4.95M 4.56M 4.27M 7.99M 544M 8.12M 20.98M 265M 21.49M 21.03M 917M	EV / Sales 2026 *	16.8x	EV / Sales 2027 *	2.71x
Free-Float	89.3%	Yield 2026 *	-	Yield 2027 *	-

06-10	Immunovia: Published study bolsters evidence for PancreaSure	FW
06-10	Immunovia Publishes Final Affirm Study Results in Journal of Clinical Oncology Confirming Strong Diagnostic Performance of Pancreasure	CI
05-07	Immunovia AB, Q1 2026 Earnings Call, May 07, 2026
05-07	Immunovia Q1 operating loss at SEK 18.4 mln	RE
05-07	Immunovia cash burn beats guidance - CEO: commercial pipeline significantly strengthened	FW
05-07	Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Immunovia launches registry study for PancreaSure	FW
05-05	Immunovia AB Launches Assure Registry To Evaluate Real-World Clinical Impact Of Pancreasure In High-Risk Pancreatic Cancer Surveillance	CI
04-10	Immunovia AB Auditor Raises 'Going Concern' Doubt	CI
03-23	96 stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
03-19	38 stocks hit new 52-week lows on Stockholm Stock Exchange so far today	FW
03-13	18 stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
03-03	Two Sigma Investments Becomes New Public Short Seller in Immunovia	FW

26/02/25	Carlsquare initiates assignment monitoring of Immunovia	FW
30/12/23	Bonesupport winner of the year and Viaplay loser of the year on Nasdaq Stockholm 2023	FW

Immunovia AB Stock London S.E.

Stocks

0G8X

SE0006091997

Advanced Medical Equipment & Technology

Valuation: Immunovia AB

Chart: Immunovia AB

Latest news : Immunovia AB

Last Transcript: Immunovia AB

Analysts' recommendations: Immunovia AB

Press Releases: Immunovia AB

Quotes and Performance

Course Extremes

Managers and Directors: Immunovia AB

Medical Diagnostic & Testing Equipment

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

06-10	Immunovia publishes final AFFIRM study results in Journal of Clinical Oncology confirming strong diagnostic performance of PancreaSure	AQ
05-13	BULLETIN FROM THE ANNUAL GENERAL MEETING ON 13 MAY 2026 IN IMMUNOVIA AB (PUBL)	AQ
05-11	Research update Immunovia, Q1 2026: Initial commercialisation phase on track	AQ
05-07	Immunovia Publishes Interim Report for January-March 2026	AQ
05-05	Immunovia launches ASSURE registry to evaluate real-world clinical impact of PancreaSure in high-risk pancreatic cancer surveillance	AQ

1 day	-32.03%
1 week	+14,213.90%
Current month	+14,213.90%
1 month	+16,833.69%
3 months	+19,603.70%
6 months	+10,869.07%
Current year	+13,658.62%

1 week	0.18	0.32
1 month	0.18	0.32
Current year	0.15	0.32
1 year	0.15	0.92
3 years	0.15	2.78
5 years	0.15	139.14
10 years	0.15	292

Manager	Title	Age	Since
Jeff Borcherding CEO	Chief Executive Officer	53	29/04/2023
Lisa Ford CTO	Chief Tech/Sci/R&D Officer	55	29/04/2024
Norma Alonzo Palma CTO	Chief Tech/Sci/R&D Officer	54	31/01/2024

Director	Title	Age	Since
Hans Olof Gunnar Johansson BRD	Director/Board Member	72	09/12/2016
Peter Andersen CHM	Chairman	69	26/05/2023
Martin Brygger Møller BRD	Director/Board Member	51	01/01/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNOVIA AB	-32.03%	+14,213.90%	-	-	12.86M
SARTORIUS AG	+0.35%	-2.32%	+12.45%	-31.39%	16.51B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	-0.23%	+0.92%	+29.99%	+69.38%	1.66B
ECKERT & ZIEGLER SE	-0.65%	-0.90%	-29.62%	+15.96%	1.11B
QUIDELORTHO CORPORATION	+0.28%	-1.40%	-51.11%	-83.54%	964M
CONTEC MEDICAL SYSTEMS CO.,LTD	+2.05%	-2.67%	-21.54%	-53.09%	649M
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	+1.38%	-3.99%	-45.73%	-56.87%	569M
VAREX IMAGING CORPORATION	+0.09%	+9.42%	+34.80%	-51.85%	465M
REVENIO GROUP OYJ	-1.57%	-4.56%	-54.16%	-63.34%	387M
CELLAVISION AB	+5.18%	+9.68%	-26.02%	-30.20%	351M
Average	-2.52%	+0.96%	-16.77%	-31.66%	2.52B
Weighted average by Cap.	+0.35%	-1.43%	+5.27%	-26.10%

	2026 *	2027 *
Net sales	3.2M 341K 294K 271K 254K 475K 32.37M 483K 1.25M 15.75M 1.28M 1.25M 54.55M	17.3M 1.84M 1.59M 1.47M 1.37M 2.57M 175M 2.61M 6.75M 85.17M 6.91M 6.76M 295M
Net income	-91M -9.68M -8.36M -7.71M -7.21M -13.52M -920M -13.73M -35.48M -448M -36.34M -35.57M -1.55B	-82M -8.73M -7.54M -6.94M -6.5M -12.18M -829M -12.37M -31.97M -404M -32.75M -32.05M -1.4B
Net Debt	-67M -7.13M -6.16M -5.67M -5.31M -9.95M -678M -10.11M -26.12M -330M -26.76M -26.19M -1.14B	-74M -7.87M -6.8M -6.27M -5.87M -10.99M -748M -11.16M -28.85M -364M -29.55M -28.92M -1.26B